Full text of accepted abstracts will be made available to media registrants on April 14, 2020, two weeks before the content goes live to the public. Abstracts will be released to the public on Tuesday, April 28, 2020 at 4:30 p.m. EST. Researchers and presenters are free to discuss the content of their abstracts throughout this embargo period, but any abstract-related content may not be published until the abstracts are publicly released online.
Updated data, new graphics, follow-up information to be presented during sessions is embargoed until 6 a.m. on the presentation day.
In exceedingly rare circumstances, ASGCT may grant an exception to the embargo policy in order to comply with regulations from the Securities and Exchange Commission (SEC), other federal law, or international law.
Any exception request must be submitted to ASGCT in writing to Executive Director David Barrett (email@example.com), Senior Education Manager David Wood (firstname.lastname@example.org), and Senior Manager of Communications Alex Wendland (email@example.com) at least 48 hours before the conclusion of the public embargo, and must include the following:
Whenever possible, ASGCT prefers any disclosure follow these guidelines:
For example, a press release stating “we’re hopeful that the research presented at the ASGCT Annual Meeting will bring gene therapy for [insert disease] closer to the clinic, and we’re excited to share additional updates during our presentation,” is a qualitative statement and preferred in the case of an exception. However, a statement such as “in the study submitted to ASGCT, 5 of 7 patients demonstrate no disease symptoms and we’ve applied for FDA fast track designation,” is a quantitative statement and should not be included in a release.
Registration and Hotel Blocks
Abstract Submission Closes
January 29, 2020
Abstract Notifications Sent
April 6, 2020
April 28, 2020
23rd ASGCT Annual Meeting
May 12 – 15, 2020
Hynes Convention Center
900 Boylston St, Boston, MA 02115